Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats

1 Geriatric Research, Education and Clinical Center, Veterans Administration Medical Center, Gainesville; and Departments of 2 Applied Physiology and Kinesiology, 3 Orthopedics and Rehabilitation, and 4 Physiological Sciences, University of Florida, Gainesville, Florida Submitted 30 July 2008 ; acce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of physiology: endocrinology and metabolism 2008-11, Vol.295 (5), p.E1213-E1222
Hauptverfasser: Yarrow, Joshua F, Conover, Christine F, Purandare, Amol V, Bhakta, Ashish M, Zheng, Naiquan, Conrad, Bryan, Altman, Molly K, Franz, Sarah E, Wronski, Thomas J, Borst, Stephen E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:1 Geriatric Research, Education and Clinical Center, Veterans Administration Medical Center, Gainesville; and Departments of 2 Applied Physiology and Kinesiology, 3 Orthopedics and Rehabilitation, and 4 Physiological Sciences, University of Florida, Gainesville, Florida Submitted 30 July 2008 ; accepted in final form 7 September 2008 High-dose testosterone enanthate (TE) may prevent hypogonadism-induced osteopenia. For this study, 3-mo-old male and female Fisher SAS rats underwent sham surgery, gonadectomy (GX), or GX plus 28 days TE administration (7.0 mg/wk). GX reduced serum sex hormones (i.e., testosterone, dihydrotestosterone, and estradiol) ( P < 0.05) in both sexes and bone concentrations of testosterone (males only), and estradiol (females only). GX also elevated urine deoxypyridinoline/creatinine in both sexes and serum osteocalcin (females only), findings that are consistent with high-turnover osteopenia. GX reduced cancellous bone volume (CBV) and increased osteoid surfaces in tibia of both sexes. GX males also experienced reduced trabecular number and width and increased trabecular separation, whereas GX females experienced increased osteoblast and osteoid surfaces. Bone biomechanical characteristics remained unaffected by GX, except that femoral stiffness was reduced in females. In contrast, TE administration to GX rats elevated serum and bone androgens to supraphysiological concentrations in both sexes but altered neither serum nor bone estradiol in males. Additionally, TE did not prevent GX-induced reductions in serum or bone estradiol in females. TE also reduced markers of high-turnover osteopenia in both sexes. In males, TE prevented GX-induced changes in trabecular number and separation, CBV, and osteoid surfaces while diminishing osteoblast and osteoclast surfaces; however, these changes were not fully prevented in females. In both sexes, TE increased femoral length and femoral maximal strength to above that of Sham and GX animals while preventing the loss of femoral stiffness in females. In conclusion, TE administration appears protective of cancellous bone in male rats and augments cortical bone strength in both sexes. androgen; osteoblast; osteoclast; osteoporosis; osteopenia Address for reprint requests and other correspondence: S. E. Borst, VA Medical Center, GRECC-182, 1601 SW Archer Rd., Gainesville FL 32608-1197 (e-mail: seborst{at}ufl.edu )
ISSN:0193-1849
1522-1555
DOI:10.1152/ajpendo.90640.2008